Executive Summary
A cluster of five 8-K filings on December 18, 2025, all disclosing notices of delisting or failure to satisfy continued listing rules (Item 3.01), signals acute distress across multiple micro-cap companies, primarily in tech, biotech, and healthcare sectors. This synchronized event suggests potential regulatory scrutiny or market-wide pressures on listing compliance, amplifying bearish sentiment and liquidity risks for small-cap equities. Portfolio managers should de-risk exposures to similar profiles amid elevated systemic delisting contagion risks.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from December 16, 2025.
Investment Signals(4)
- ▲
Cluster of delisting notices across five companies on single day BEARISH - Reliance Global Group, VerifyMe, Neuphoria Therapeutics, Cambium Networks, Cosmos Health
- ▲
Critical risk levels (4/5 at critical) with 10/10 materiality BEARISH - All filers
- ▲
Governance deterioration via director/officer departures BEARISH - Cambium Networks
- ▲
Uniform lack of quantitative disclosures heightens uncertainty BEARISH - All companies
Risk Flags(3)
- ▼
Synchronized delisting cluster indicates potential regulatory sweep or small-cap compliance purge, risking broader index contagion
- ▼
Liquidity evaporation and institutional selling pressure post-delisting across diverse micro-caps
- ▼
Opaque failure reasons (all NOT_DISCLOSED) amplify financial distress uncertainty
Opportunities(3)
- ◆
Pre-delisting short opportunities if trading remains active BEARISH - Reliance Global Group, others
- ◆
Monitor for OTC transitions or distress M&A as rebound plays HIGH-RISK - All delisted firms
- ◆
Avoid long exposure but screen peers for relative strength in compliant small-caps
Sector Themes(3)
- ◆
Micro-cap tech/biotech/healthcare cohort under listing compliance pressure, with failures in networking (Cambium), therapeutics (Neuphoria), and health (Cosmos)
- ◆
Governance erosion compounding delistings, as seen in multi-item filings with officer departures
- ◆
Absence of detailed catalysts points to uniform financial/market cap deficiencies
Watch List(4)
- 👁
Cambium Networks Corp - Multi-risk (delisting + governance changes) for accelerated downside
- 👁
Reliance Global Group, Cosmos Health - Exhibit disclosures (Item 9.01) may reveal compliance details
- 👁
Peer micro-caps (<$100M mkt cap) in tech/health - Contagion from cluster delistings
- 👁
US exchange small-cap listings - Systemic halt patterns post-Dec 18
Filing Analyses(5)
18-12-2025
Reliance Global Group, Inc. filed a Form 8-K on December 18, 2025, reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 9.01 discloses Financial Statements and Exhibits. No additional details, numerical values, or transaction specifics are provided in the filing summary.
- ·Items reported: 3.01 (delisting notice) and 9.01 (financials/exhibits)
- ·Multi-item mandatory 8-K filing on delisting event
- ·Core event: Notice of delisting or listing rule failure; all other metrics (value, impact, financials) NOT_DISCLOSED
18-12-2025
VerifyMe, Inc. filed an 8-K on December 18, 2025 (AccNo: 0001214659-25-018223), reporting under Item 3.01 a notice of delisting or failure to satisfy continued US exchange listing rules. This is a mandatory disclosure of a material negative event with no additional details on reasons, financial impacts, or transaction values provided. Delisting typically impairs liquidity and investor access.
- ·Single-item 8-K filing under Item 3.01 (Notice of Delisting or Failure to Satisfy Listing Rule)
- ·Event dated December 18, 2025; filed same day, likely within 4-business-day requirement
- ·No quantitative data (e.g., transaction value, share count: NOT_DISCLOSED); sector not specified
18-12-2025
Neuphoria Therapeutics Inc. filed an 8-K on December 18, 2025, reporting under Item 3.01 a notice of delisting or failure to satisfy continued listing rules from the US market. No additional details on reasons, financial impacts, or transaction values are disclosed in the provided filing summary. This event signals potential liquidity and visibility loss for shareholders.
- ·Single-item 8-K filing under Item 3.01 (Notice of Delisting or Failure to Satisfy Listing Rule).
- ·Core event: Delisting notice; all quantitative data (transaction value, shares, financial metrics) NOT_DISCLOSED.
- ·Sector not specified; no related filings, insider activity, or guidance changes mentioned.
18-12-2025
Cambium Networks Corp filed an 8-K on December 18, 2025, reporting a notice of delisting or failure to satisfy continued listing rules (Item 3.01) and departure of directors or certain officers (Item 5.02), with exhibits under Item 9.01. This is a multi-item mandatory disclosure signaling significant listing and governance issues. No financial metrics, transaction values, or detailed event descriptions are provided in the filing summary.
- ·Items reported: 3.01 (Delisting notice), 5.02 (Director/officer departures), 9.01 (Exhibits)
- ·Multi-item filing; mandatory disclosures
- ·Filed same day as event date (2025-12-18), likely within 4-business-day requirement
18-12-2025
Cosmos Health Inc. filed an 8-K on December 18, 2025, under Items 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule) and 9.01 (Financial Statements and Exhibits), indicating a delisting event from US markets. No specific details on reasons, values, or impacts are disclosed in the provided summary. This is a material negative event signaling listing non-compliance.
- ·Items 3.01 and 9.01 reported in multi-item 8-K filing.
- ·Core event: Notice of delisting or failure to satisfy listing standards.
- ·No quantitative data (transaction value, shares, financial metrics) disclosed.
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 5 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC